Wanbo Liu1, Sheng Chen2, Bing Liu3. 1. Department of Medical Affairs, The General Hospital of the PLA Rocket Force, Beijing, China. 2. Department of General Surgery, The General Hospital of the PLA Rocket Force, Beijing, China. 3. Center for Disease Prevention and Control of Rocket Force, No. 109, Beiqing Road, Haidian distinct, Beijing, 100032, China. liubehbh@126.com.
Abstract
BACKGROUND: Hepatoblastoma (HB) is the most common primary malignant tumor of the liver in young children. The aim of this study is to identify the diagnostic and prognostic values of serum exosomal miR-21 in Chinese patients with HB. METHODS: We retrospectively reviewed 32 children with HB. The expressions of miR-21 were detected by real-time PCR. The comparison of diagnostic performance of plasmatic, exosomal miR-21 and AFP levels was measured using the Area Under ROC Curve. RESULTS: For patients in HB group, miR-21 concentration was significantly higher in the exosomes compared with the exosome-depleted supernatants and whole plasma. Expression of miR-21 was significantly higher in patients with HB compared with control group in both plasma and exosomes. With respect to the diagnosis of patients with HB, exosomal miR-21 was significantly more accurate compared with the Alpha-fetoprotein levels. Moreover, exosomal miR-21 was an independent predictor of Even-free survival for patients with HB. CONCLUSIONS: In this study, we found that expression of miR-21 was significantly higher in patients with HB compared with control group in both plasma and exosomes, and we confirmed that exosomal miR-21 could be defined as a diagnostic and prognostic biomarker for patients with HB.
BACKGROUND:Hepatoblastoma (HB) is the most common primary malignant tumor of the liver in young children. The aim of this study is to identify the diagnostic and prognostic values of serum exosomal miR-21 in Chinese patients with HB. METHODS: We retrospectively reviewed 32 children with HB. The expressions of miR-21 were detected by real-time PCR. The comparison of diagnostic performance of plasmatic, exosomal miR-21 and AFP levels was measured using the Area Under ROC Curve. RESULTS: For patients in HB group, miR-21 concentration was significantly higher in the exosomes compared with the exosome-depleted supernatants and whole plasma. Expression of miR-21 was significantly higher in patients with HB compared with control group in both plasma and exosomes. With respect to the diagnosis of patients with HB, exosomal miR-21 was significantly more accurate compared with the Alpha-fetoprotein levels. Moreover, exosomal miR-21 was an independent predictor of Even-free survival for patients with HB. CONCLUSIONS: In this study, we found that expression of miR-21 was significantly higher in patients with HB compared with control group in both plasma and exosomes, and we confirmed that exosomal miR-21 could be defined as a diagnostic and prognostic biomarker for patients with HB.
Authors: D von Schweinitz; D J Byrd; H Hecker; P Weinel; U Bode; D Bürger; R Erttmann; D Harms; H Mildenberger Journal: Eur J Cancer Date: 1997-07 Impact factor: 9.162
Authors: Mónika Gyugos; Gábor Lendvai; István Kenessey; Krisztina Schlachter; Judit Halász; Péter Nagy; Miklós Garami; Zsuzsa Jakab; Zsuzsa Schaff; András Kiss Journal: Virchows Arch Date: 2014-02-26 Impact factor: 4.064
Authors: J B Otte; J Pritchard; D C Aronson; J Brown; P Czauderna; R Maibach; G Perilongo; E Shafford; J Plaschkes Journal: Pediatr Blood Cancer Date: 2004-01 Impact factor: 3.167
Authors: Jörg Fuchs; Jana Rydzynski; Dietrich Von Schweinitz; Udo Bode; Hartmut Hecker; Peter Weinel; Dietrich Bürger; Dieter Harms; Rudolf Erttmann; Karl Oldhafer; Hermann Mildenberger Journal: Cancer Date: 2002-07-01 Impact factor: 6.860
Authors: Rebecka L Meyers; Jon R Rowland; Mark Krailo; Zhengjia Chen; Howard M Katzenstein; Marcio H Malogolowkin Journal: Pediatr Blood Cancer Date: 2009-12 Impact factor: 3.167
Authors: Angela Galardi; Marta Colletti; Virginia Di Paolo; Patrizia Vitullo; Loretta Antonetti; Ida Russo; Angela Di Giannatale Journal: Int J Mol Sci Date: 2019-09-17 Impact factor: 5.923
Authors: Ainhoa Lapitz; Ander Arbelaiz; Paula Olaizola; Aitziber Aranburu; Luis Bujanda; Maria J Perugorria; Jesus M Banales Journal: Front Immunol Date: 2018-10-12 Impact factor: 7.561